Abstract:We read the study by Durila et al 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar with interest; however, we seek several clarifications. First, a separate study by Yu et al 2 Yu ES, Jeon MJ, Kang KW, et al. The role of platelet function analyzer-200 in predicting perioperative bleeding risk [e-pub ahead of print]. Korean J Intern Med. doi:10.3904/kjim.2019.112, accessed September 9, 2020. Google Scholar showed that the results of platelet function analyzer 200 (PFA 200) are influenced by various factors, such as the use of aspirin and other non-steroidal anti-inflammatory agents, blood group type, hematocrit and time of blood collection, transfusions, and underlying diseases. The severity of surgery might cause bleeding, which affects collagen–epinephrine and collagen–adenosine diphosphate. The conclusion that the pathology of primary hemostasis detected by the PFA 200 (collagen–epinephrine and collagen–adenosine diphosphate) was specific for the extracorporeal membrane oxygenation (ECMO) phase of surgery is not robust and is subject to confounding bias. 3 Zhang Z Model building strategy for logistic regression: purposeful selection. Ann Transl Med. 2016; 4: 111 Crossref PubMed Scopus (192) Google Scholar Second, a continuous intravenous infusion of low-molecular-weight heparin was used to prevent venous thromboprophylaxis, but without dose described. Piwowarczyk et al 4 Piwowarczyk P, Borys M, Kutnik P, et al. Unfractionated heparin versus subcutaneous nadroparin in adults supported with venovenous extracorporeal membrane oxygenation: a retrospective, multicenter study [e-pub ahead of print]. ASAIO J. doi:10.1097/MAT.0000000000001166, accessed September 9, 2020. Google Scholar compared nadroparin with unfractionated heparin during veno-venous ECMO and found no significant difference in the number of thrombotic and hemorrhagic events. In the paper by Durila et al, 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar even with the use of continuous intravenous infusion of low-molecular-weight heparin, 2 patients suffered thrombotic events. Third, the duration of the ECMO in their work is short (5 ± 3 days). The effect of duration of support on outcomes was not provided because we would suggest that the risk of thrombotic events is lower with a shorter duration of ECMO support. Given these considerations, it is difficult for us to completely agree with the conclusion that the PFA 200 analyzer may be used to prevent circuit thrombosis instead of using unfractionated heparin in patients on prolonged ECMO. We believe that a point-of-care test such as the PFA 200 may assist in adjusting anti-coagulant strategy to potentially reduce the use of unfractionated heparin rather than to prevent circuit thrombosis and obviate the use of unfractionated heparin altogether, especially in patients on prolonged ECMO support.

Platelet factor-4 concentration in adult veno-arterial ECMO patients

Frequency and Clinical Impact of Platelet Factor 4-Specific Antibodies in Patients Undergoing Extracorporeal Membrane Oxygenation

Heparin-Induced Thrombocytopenia in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation

Heparin-induced thrombocytopenia in extracorporeal membrane oxygenation-supported patients: a systematic review and meta-analysis

Hemostasis During Extracorporeal Membrane Oxygenation: More Questions

Absolute Immature Platelet Counts in the Setting of Suspected Heparin-Induced Thrombocytopenia May Predict Anti-Pf4-heparin Immunoassay Testing Results

Effect of Unfractionated Heparin Dose on Complement Activation and Selected Extracellular Vesicle Populations during Extracorporeal Membrane Oxygenation

Outcomes of heparinized adult veno-arterial extracorporeal membrane oxygenation patients managed with low and high activated partial thromboplastin time targets: A systematic review and meta-analysis

Anti-factor Xa vs aPTT for heparin monitoring in extracorporeal membrane oxygenation

Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial

Heparin Dosing Regimen Optimization in Veno-Arterial Extracorporeal Membrane Oxygenation: A Pharmacokinetic Analysis

Heparin-induced thrombocytopenia with very high antibody titer is associated with slower platelet recovery and higher risk of thrombosis

Thromboelastography versus thromboelastometry for unfractionated heparin monitoring in adult patients on extracorporeal membrane oxygenation

Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles?

Association of Metal Cations with the Anti-PF4/Heparin Antibody Response in Heparin-Induced Thrombocytopenia

Anti-PF4 ELISA-Negative, SRA-Positive Heparin-Induced Thrombocytopenia

Variable serotonin release assay pattern and specificity of PF4-specific antibodies in HIT, and clinical relevance

Discordance among assays for monitoring? Anticoagulation during extracorporeal life support

Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA?

Whole-blood Point-of-Care Activated Partial Thromboplastin Time Ratio (APR) is not Accurate Enough to Monitor Heparin Therapy in Patients with Severe Respiratory Failure Secondary to SARS-Cov-2 Infection Supported with Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)